SCHEMBL772797

SCHEMBL772797

CS(=O)(=O)OCCn1ncc(-c2nc(-c3cc(F)ccc3F)no2)c1-c1ccccc1

nearest known ligand 0.69

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
S1PR1 P21453 11/20 0.69
NPC1 O15118 4/20 0.38
RAB9A P51151 4/20 0.38
SMN1; SMN2 Q16637 2/20 0.38
L3MBTL1 Q9Y468 2/20 0.38
MEN1 O00255 1/20 0.38
PKM P14618 1/20 0.38
NFKB1 P19838 1/20 0.38
MAPK1 P28482 1/20 0.38
NFKB2 Q00653 1/20 0.38
KMT2A Q03164 1/20 0.38
RELA Q04206 1/20 0.38
ALDH1A1 P00352 2/20 0.37
KDM4E B2RXH2 1/20 0.37
GLA P06280 1/20 0.37
HPGD P15428 1/20 0.37
HSD17B10 Q99714 1/20 0.37
MAOA P21397 1/20 0.36
BLVRB P30043 1/20 0.36
HDAC6 Q9UBN7 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL773443 0.85 S1PR1 (0.80) S1PR1NPC1RAB9ASMN1; SMN2L3MBTL1
SCHEMBL773462 0.83 S1PR1 (0.76) S1PR1NPC1RAB9ASMN1; SMN2L3MBTL1
SCHEMBL772453 0.82 S1PR1 (1.00) S1PR1NPC1RAB9ASMN1; SMN2L3MBTL1
SCHEMBL798035 0.81 S1PR1 (1.00) S1PR1NPC1RAB9ASMN1; SMN2L3MBTL1
SCHEMBL15929388 0.81 S1PR1 (0.78) S1PR1NPC1RAB9ASMN1; SMN2L3MBTL1
SCHEMBL774522 0.79 S1PR1 (0.68) S1PR1NPC1RAB9ASMN1; SMN2L3MBTL1
SCHEMBL772895 0.77 S1PR1 (0.72) S1PR1NPC1RAB9AL3MBTL1PKM
SCHEMBL771288 0.76 S1PR1 (0.74) S1PR1NPC1RAB9ASMN1; SMN2L3MBTL1
SCHEMBL774088 0.76 S1PR1 (0.73) S1PR1NPC1RAB9APKMKMT2A
SCHEMBL773147 0.76 S1PR1 (1.00) S1PR1NPC1RAB9ASMN1; SMN2L3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2440554-B1 PYRAZOLE OXADIAZOLE DERIVATIVES AS S1P1 AGONISTS MERCK SERONO SA (CH) 2016-10-05 EP disclosed
US-8802663-B2 Pyrazole oxadiazole derivatives as S1P1 agonists MERCK SERONO SA (CH) 2014-08-12 US disclosed
EP-2440554-A1 PYRAZOLE OXADIAZOLE DERIVATIVES AS S1P1 AGONISTS Merck Serono S.A. (CH) 2012-04-18 EP disclosed
US-20120071460-A1 PYRAZOLE OXADIAZOLE DERIVATIVES AS S1P1 AGONISTS MERCK SERONO SA (CH) 2012-03-22 US disclosed
WO-2010142628-A1 PYRAZOLE OXADIAZOLE DERIVATIVES AS S1P1 AGONISTS MERCK SERONO S.A. (CH) 2010-12-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120071460-A1 PYRAZOLE OXADIAZOLE DERIVATIVES AS S1P1 AGONISTS S1PR1, S1PR3, S1PR2 S1PR1 1/4885NPC1 734/4885RAB9A 3147/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.